SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India

Introduction. The second wave of COVID-19 has spread across India causing unprecedented misery to people since March 2021. Kidney transplant recipients (KTRs) are at an increased risk of severe infection. Their outcomes appear to be worse than those in the general population. There is no robust evid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ravi Raju Tatapudi, Venkateswara Rao Kopparti, Anusha Poosapati, Srinivas Metta, Atchyutha Rao Gongada, Balakrishna Vedulla
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/b67a02fb3b8d481cab1c8f60773d1dd3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b67a02fb3b8d481cab1c8f60773d1dd3
record_format	dspace
spelling	oai:doaj.org-article:b67a02fb3b8d481cab1c8f60773d1dd32021-11-15T01:19:10ZSARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India2090-215810.1155/2021/2243095https://doaj.org/article/b67a02fb3b8d481cab1c8f60773d1dd32021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2243095https://doaj.org/toc/2090-2158Introduction. The second wave of COVID-19 has spread across India causing unprecedented misery to people since March 2021. Kidney transplant recipients (KTRs) are at an increased risk of severe infection. Their outcomes appear to be worse than those in the general population. There is no robust evidence or consensus to support any form of treatment protocol or modification of immunosuppression in KTRs with COVID-19. There is a need to develop effective and safe therapeutic protocols for this frail population. Remdesivir is the only approved antiviral drug in COVID-19 till now. Methods. We describe clinical features, role of HRCT, therapeutic protocols, and mortality rate of 20 KTRs with SARS-CoV-2 infection. Results. Complete recovery was seen in 8 (40%) patients monitored at home. 12 (60%) patients with HRCT scores more than 8/25 were hospitalized. 11 (55%) had hypoxia, of these 8 (40%) had mild hypoxia, 1 (5%) required NIV, and 2 (10%) needed mechanical ventilation. Immunosuppression was modified in all the patients. Remdesivir and dexamethasone were administered to the hospitalized patients. 1 (5%) patient had AKI requiring RRT. 1 (5%) patient expired, and 1 still hospitalized. 10 of the hospitalized patients recovered. Out of the total 20 patients, 18 (90%) recovered completely within two weeks of infection. Conclusion. Clinical presentation of COVID-19 in KTRs was similar to nontransplant patients. Early hospitalisation and assessing the severity by HRCT were important. Continuing tacrolimus and administering remdesivir and dexamethasone reduced the incidence of renal failure and improved survival rates.Ravi Raju TatapudiVenkateswara Rao KoppartiAnusha PoosapatiSrinivas MettaAtchyutha Rao GongadaBalakrishna VedullaHindawi LimitedarticleDiseases of the genitourinary system. UrologyRC870-923ENInternational Journal of Nephrology, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Ravi Raju Tatapudi Venkateswara Rao Kopparti Anusha Poosapati Srinivas Metta Atchyutha Rao Gongada Balakrishna Vedulla SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
description	Introduction. The second wave of COVID-19 has spread across India causing unprecedented misery to people since March 2021. Kidney transplant recipients (KTRs) are at an increased risk of severe infection. Their outcomes appear to be worse than those in the general population. There is no robust evidence or consensus to support any form of treatment protocol or modification of immunosuppression in KTRs with COVID-19. There is a need to develop effective and safe therapeutic protocols for this frail population. Remdesivir is the only approved antiviral drug in COVID-19 till now. Methods. We describe clinical features, role of HRCT, therapeutic protocols, and mortality rate of 20 KTRs with SARS-CoV-2 infection. Results. Complete recovery was seen in 8 (40%) patients monitored at home. 12 (60%) patients with HRCT scores more than 8/25 were hospitalized. 11 (55%) had hypoxia, of these 8 (40%) had mild hypoxia, 1 (5%) required NIV, and 2 (10%) needed mechanical ventilation. Immunosuppression was modified in all the patients. Remdesivir and dexamethasone were administered to the hospitalized patients. 1 (5%) patient had AKI requiring RRT. 1 (5%) patient expired, and 1 still hospitalized. 10 of the hospitalized patients recovered. Out of the total 20 patients, 18 (90%) recovered completely within two weeks of infection. Conclusion. Clinical presentation of COVID-19 in KTRs was similar to nontransplant patients. Early hospitalisation and assessing the severity by HRCT were important. Continuing tacrolimus and administering remdesivir and dexamethasone reduced the incidence of renal failure and improved survival rates.
format	article
author	Ravi Raju Tatapudi Venkateswara Rao Kopparti Anusha Poosapati Srinivas Metta Atchyutha Rao Gongada Balakrishna Vedulla
author_facet	Ravi Raju Tatapudi Venkateswara Rao Kopparti Anusha Poosapati Srinivas Metta Atchyutha Rao Gongada Balakrishna Vedulla
author_sort	Ravi Raju Tatapudi
title	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
title_short	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
title_full	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
title_fullStr	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
title_full_unstemmed	SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India
title_sort	sars-cov-2 infection in kidney transplant recipients: a single-centre study of 20 cases from india
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/b67a02fb3b8d481cab1c8f60773d1dd3
work_keys_str_mv	AT ravirajutatapudi sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia AT venkateswararaokopparti sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia AT anushapoosapati sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia AT srinivasmetta sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia AT atchyutharaogongada sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia AT balakrishnavedulla sarscov2infectioninkidneytransplantrecipientsasinglecentrestudyof20casesfromindia
_version_	1718429005776945152

SARS-CoV-2 Infection in Kidney Transplant Recipients: A Single-Centre Study of 20 Cases from India

Ejemplares similares